Crescent Biopharma Announces Grants of Inducement Awards

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards totaling 24,600 shares to two non-executive employees approved February 17, 2026. The options have a 10-year term and an exercise price of $9.33, the February 17, 2026 closing price.

Vesting: 1/4 after one year from each employee's start date, then 1/48 monthly thereafter, subject to continuous service and plan terms.

Key Figures

Current share price: $9.72 Inducement options granted: 24,600 shares Number of employees: 2 employees +5 more

8 metrics

Current share price $9.72 Pre-news trading level for CBIO

Inducement options granted 24,600 shares Aggregate options granted to two non-executive employees

Number of employees 2 employees Recipients of inducement option awards

Option exercise price $9.33 Exercise price equal to Nasdaq closing price on Feb 17, 2026

Option term 10 years Contractual life of inducement stock options

Initial vesting cliff 1/4th at 1 year 25% of option vests on first anniversary of start date

Ongoing vesting rate 1/48th monthly Remaining shares vest monthly after first anniversary

Approval date February 17, 2026 Date Compensation Committee approved inducement options

Market Reality Check

Price: $9.72 Vol: Volume 189,572 is below t...

normal vol

$9.72 Last Close

Volume Volume 189,572 is below the 20-day average of 221,201 ahead of this HR-focused news. normal

Technical Shares at $9.72 are trading below the 200-day MA of $10.84 and at the 52-week low.

Peers on Argus

Peers show mixed moves, with names like CRBU up 4.52% and NVCT down 2.92%, sugge...

Peers show mixed moves, with names like CRBU up 4.52% and NVCT down 2.92%, suggesting CBIO’s 4.18% gain is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Conference appearance	Neutral	-3.1%	Planned management fireside chat at Guggenheim biotech summit with webcast access.
Jan 30	Inducement awards	Neutral	+2.4%	Inducement equity option awards totaling 117,339 options to five new employees.
Jan 05	IND clearances	Positive	+0.3%	IND clearances for CR-001 and CR-003 and plans for ASCEND Phase 1/2 trial.
Dec 18	Inducement awards	Neutral	-3.0%	129,626 options granted to three employees under 2025 Inducement Plan.
Dec 04	Partnership & funding	Positive	-4.2%	$185M private placement and strategic Kelun-Biotech partnership expanding pipeline.

Pattern Detected

Recent news spans HR-related inducement awards, a major partnership/financing, and key regulatory clearances, with mostly aligned price reactions and one notable selloff on positive partnership news.

Recent Company History

Over the last few months, Crescent Biopharma has combined strategic financing, pipeline progress, and recurring inducement grants. The December 2025 Kelun-Biotech partnership with a $185 million private placement supported multiple planned Phase 1/2 trials. IND clearances for CR-001 and CR-003 on January 5, 2026 modestly lifted shares. Subsequent inducement option awards in December 2025 and January 2026 produced mixed but generally aligned trading responses. Today’s smaller inducement grants fit this pattern of ongoing equity-based hiring alongside pipeline build-out.

Market Pulse Summary

This announcement details standard inducement option grants—24,600 shares at a $9.33 exercise price ...

Analysis

This announcement details standard inducement option grants—24,600 shares at a $9.33 exercise price with a four-year vesting schedule—used to attract non-executive talent. It follows prior rounds of employee equity awards and comes after significant milestones such as IND clearances and a $185 million partnership financing. Investors tracking Crescent may focus on how this growing team supports execution of multiple planned Phase 1/2 trials and future regulatory catalysts.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 24,600 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on February 17, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $9.33, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on February 17, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contact

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

FAQ

What did Crescent Biopharma (CBIO) approve on February 17, 2026 regarding inducement awards?

Crescent approved options to purchase an aggregate of 24,600 shares as inducement awards on February 17, 2026. According to the company, the grants were material to each employee's acceptance and comply with Nasdaq Listing Rule 5635(c)(4).

What are the exercise price and term for the CBIO inducement options granted February 17, 2026?

The options carry an exercise price of $9.33 and a 10-year term. According to the company, $9.33 was the closing price per share on February 17, 2026 as reported by Nasdaq.

How do the inducement options for Crescent Biopharma (CBIO) vest for new employees?

Each option vests 1/4 of shares on the first employment anniversary, then 1/48 of shares monthly thereafter. According to the company, vesting is subject to continuous service and the terms of the Inducement Plan and option agreement.

Why did Crescent Biopharma (CBIO) grant inducement awards to the two employees?

The awards were approved as equity inducements and were deemed material to each employee's acceptance of employment. According to the company, this aligns with Nasdaq Listing Rule 5635(c)(4) requirements for inducement grants.

Are the CBIO inducement options subject to additional terms or agreements?

Yes. The options are governed by the Crescent Biopharma 2025 Employment Inducement Incentive Award Plan, as amended, and separate option agreements. According to the company, grant and exercise terms follow those plan provisions.